FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer By Ogkologos - July 11, 2025 594 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR ASCO 2023 roundup: Blood tests, drugs and exercise June 12, 2023 Mom’s Early-Stage Breast Cancer Discovered When She Undergoes Testing to Donate... August 21, 2019 Routes to a healthier shopping journey – how your supermarket environment... April 19, 2023 A Favourable Benefit-Risk Profile for Taletrectinib in TKI-Naїve and Crizotinib-Pretreated Patients... July 24, 2024 Load more HOT NEWS Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death... Cancer in My Community: Reducing Tobacco Use in Tunisia From smouldering ash to a gleaming temple for cancer research: The... Adjuvant Treatment with Nivolumab Plus Ipilimumab Combination Fails to Improve DFS...
